retatrutide triple agonist gip glp-1 glucagon receptor is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Quantity:3-Bottles exclude_rebuy_reorder GLP-1 Up

retatrutide triple agonist gip glp-1 glucagon receptor is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Quantity:3-Bottles exclude_rebuy_reorder GLP-1 Up

GLP-1 Up

It is being studied in clinical trials, and Lilly has reported positive Phase 3 topline results, but investigational results are not the same as FDA approval

exclude_rebuy_reorder

Quantity:3-Bottles

MDWatch also offers the Medicare GLP-1 Bridge Program — FDA-approved GLP-1s for as little as a $50 copay, if you qualify